Literature DB >> 22901308

S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial.

Amit Sood1, Kavita Prasad, Ivana T Croghan, Darrell R Schroeder, Shawna L Ehlers, Jon O Ebbert.   

Abstract

OBJECTIVES: S-Adenosyl-L-methionine (SAMe) is a dietary supplement commonly used to treat depression. SAMe facilitates dopamine and norepinephrine synthesis in the central nervous system. This study investigated the efficacy of SAMe for increasing tobacco abstinence among cigarette smokers.
DESIGN: A randomized, blinded, placebo-controlled, three-arm, dose-ranging clinical trial was conducted. Subjects were randomly allocated to receive SAMe 1600 mg or 800 mg by mouth every day or a matching placebo for 8 weeks. All subjects received a behavioral smoking cessation intervention. Self-reported smoking abstinence was biochemically confirmed with exhaled-air carbon monoxide.
SUBJECTS: Subjects in the study comprised 120 adults.
RESULTS: One hundred and twenty (120) subjects with a mean age of 40.0±14.0 (SD) years were enrolled. Participants smoked an average of 19.6±8.6 cigarettes per day for 21±13.2 years. The study dropout rate was high (42.5%). By intention-to-treat analysis, no significant differences were observed in abstinence rates at 8 and 24 weeks between SAMe dose groups and placebo. SAMe did not attenuate withdrawal symptoms among abstinent subjects. Rates of gastrointestinal side-effects were higher with SAMe 1600 mg/d compared to placebo.
CONCLUSIONS: SAMe did not increase smoking abstinence rates. Abstinence and tobacco withdrawal data from this clinical trial suggest that SAMe holds little promise for the treatment of tobacco dependence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901308      PMCID: PMC3429269          DOI: 10.1089/acm.2011.0462

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  24 in total

Review 1.  S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease.

Authors:  M L Hardy; I Coulter; S C Morton; J Favreau; S Venuturupalli; F Chiappelli; F Rossi; G Orshansky; L K Jungvig; E A Roth; M J Suttorp; P Shekelle
Journal:  Evid Rep Technol Assess (Summ)       Date:  2003-08

2.  The antidepressant potential of oral S-adenosyl-l-methionine.

Authors:  J F Rosenbaum; M Fava; W E Falk; M H Pollack; L S Cohen; B M Cohen; G S Zubenko
Journal:  Acta Psychiatr Scand       Date:  1990-05       Impact factor: 6.392

3.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

Review 4.  Effects of abstinence from tobacco: valid symptoms and time course.

Authors:  John R Hughes
Journal:  Nicotine Tob Res       Date:  2007-03       Impact factor: 4.244

5.  Optimising the design of phase II oncology trials: the importance of randomisation.

Authors:  Mark J Ratain; Daniel J Sargent
Journal:  Eur J Cancer       Date:  2008-12-06       Impact factor: 9.162

6.  Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography.

Authors:  Bernd Saletu; Peter Anderer; Carlo Di Padova; Alessandro Assandri; Gerda Maria Saletu-Zyhlarz
Journal:  Am J Clin Nutr       Date:  2002-11       Impact factor: 7.045

7.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

Review 8.  Bupropion sustained release for treatment of tobacco dependence.

Authors:  J Taylor Hays; Jon O Ebbert
Journal:  Mayo Clin Proc       Date:  2003-08       Impact factor: 7.616

9.  Measures of abstinence in clinical trials: issues and recommendations.

Authors:  John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2003-02       Impact factor: 4.244

Review 10.  The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders.

Authors:  T Bottiglieri; K Hyland; E H Reynolds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

View more
  4 in total

1.  Antidepressants for smoking cessation.

Authors:  Seth Howes; Jamie Hartmann-Boyce; Jonathan Livingstone-Banks; Bosun Hong; Nicola Lindson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-22

Review 2.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

Review 3.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

4.  Effectiveness of stop smoking interventions among adults: protocol for an overview of systematic reviews and an updated systematic review.

Authors:  Mona Hersi; Gregory Traversy; Brett D Thombs; Andrew Beck; Becky Skidmore; Stéphane Groulx; Eddy Lang; Donna L Reynolds; Brenda Wilson; Steven L Bernstein; Peter Selby; Stephanie Johnson-Obaseki; Douglas Manuel; Smita Pakhale; Justin Presseau; Susan Courage; Brian Hutton; Beverley J Shea; Vivian Welch; Matt Morrow; Julian Little; Adrienne Stevens
Journal:  Syst Rev       Date:  2019-01-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.